Boston Scientific Corporation $BSX Shares Purchased by Waycross Partners LLC

Waycross Partners LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 13.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 308,313 shares of the medical equipment provider’s stock after acquiring an additional 37,083 shares during the period. Boston Scientific accounts for 1.0% of Waycross Partners LLC’s investment portfolio, making the stock its 29th biggest position. Waycross Partners LLC’s holdings in Boston Scientific were worth $13,458,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific during the first quarter valued at $28,000. Nvwm LLC raised its position in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 542 shares during the period. Rakuten Securities Inc. acquired a new position in Boston Scientific during the second quarter valued at $30,000. Finally, Kings Path Partners LLC purchased a new stake in Boston Scientific in the 3rd quarter worth about $31,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX traded down $1.82 during midday trading on Friday, reaching $42.82. 14,710,150 shares of the company’s stock were exchanged, compared to its average volume of 18,989,676. The company’s 50 day simple moving average is $44.32 and its two-hundred day simple moving average is $55.70. The firm has a market capitalization of $62.05 billion, a PE ratio of 18.14, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. Equities research analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BSX. Truist Financial decreased their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Barclays cut their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Friday, October 30th. UBS Group reduced their target price on Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, October 29th. Argus cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Finally, Robert W. Baird increased their price target on Boston Scientific from $50.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.